Core Insights - The new drug directory includes 114 newly added drugs, focusing on key areas such as cancer and rare diseases, complementing the basic medical insurance directory [1][2] - The implementation of the updated drug directory will take effect on January 1, 2026, and will be valid until December 31, 2026 [1] Group 1: National Drug Directory Adjustments - A total of 114 drugs have been added to the national directory, with 29 drugs removed; the updated directory now includes 3,253 drugs [2] - Among the newly added drugs, 111 are new products launched within the last five years, with 36 being cancer medications and 10 for rare diseases, enhancing coverage for critical areas [2] - A six-month transition period will be provided for drugs that were removed from the negotiation list to ensure continuity of medication [2] Group 2: Commercial Health Insurance Innovation - The first version of the commercial health insurance innovation drug directory includes 19 drugs, focusing on high-value innovative treatments not fully covered by basic medical insurance [3] - The directory features 9 new drugs and includes 5 CAR-T products, highlighting significant advancements in treatment options [3] - The commercial insurance directory serves as a reference for insurance companies and does not guarantee reimbursement, as it depends on the specific insurance policy [3] Group 3: Payment Standards and Drug Access - The Hunan Provincial Medical Insurance Bureau has established self-payment ratios for the new drug directory, with Class A drugs having a self-payment ratio of 0% [4] - The province aims to facilitate the inclusion of new drugs in hospitals and has mandated local medical insurance departments to guide medical institutions in the proper use of listed drugs [4] - The payment for work-related injury and maternity insurance will not differentiate between Class A and Class B drugs, covering the full cost [4]

Core Points - The National Healthcare Security Administration (NHSA) has released the interim results of expert reviews for the 2025 National Basic Medical Insurance Directory and the Commercial Insurance Innovative Drug Directory [1] - Companies can access the evaluation results through the National Medical Insurance Service Platform, specifically in the "2025 Basic Medical Insurance Directory and Commercial Insurance Innovative Drug Directory Adjustment" module [1] - The evaluation results categorize drugs as "proposed for negotiation addition," "proposed for competitive bidding addition," or "proposed for price negotiation," indicating eligibility for negotiation or bidding but not confirmation of inclusion in the directories [1]

Core Viewpoint - The collaboration between basic medical insurance and commercial health insurance in China is advancing significantly, with new measures and systems being implemented to enhance efficiency and accessibility for patients [1][2][3][4]. Group 1: Policy Developments - The first national "medical insurance + commercial insurance" clearing settlement center has begun operations in Beijing, reducing the time lag in claims settlement between the two systems [1]. - A joint initiative by the Shanghai Financial Regulatory Bureau and seven other departments has been launched to promote the high-quality development of commercial health insurance, focusing on payment mechanisms and data sharing [1][2]. - The preliminary review of the innovative drug directory for commercial insurance, which includes several high-priced cancer drugs, has been completed, providing new payment avenues for innovative drugs [1][2]. Group 2: Market Insights - As of 2024, the basic medical insurance system covers 1.326 billion people, maintaining a coverage rate of 95%, with total fund expenditures reaching 2.97 trillion yuan [2]. - The commercial health insurance market is experiencing rapid growth, with original insurance premium income reaching 977.3 billion yuan in 2024, a year-on-year increase of 8.2% [2]. - Despite the growth, there remains significant room for improvement in the coverage and effectiveness of commercial health insurance compared to the over 95% utilization rate of basic medical insurance funds [2]. Group 3: Operational Enhancements - The new clearing settlement center allows patients to complete basic insurance reimbursement and directly use commercial insurance for remaining costs, streamlining the payment process [2][3]. - The National Medical Insurance Administration is exploring synchronized settlement between basic and commercial health insurance, aiming to reduce patient burden through data sharing [3]. - Future developments will include collaborative efforts to expand the coverage of commercial health insurance and enhance the integration of data and regulatory frameworks between the two systems [4].

Core Points - The National Healthcare Security Administration (NHSA) announced the preliminary review of the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance drug catalog adjustments [1] - The adjustment process includes multiple stages: enterprise declaration, formal review, expert evaluation, and price negotiation [1] - Passing the preliminary formal review indicates that a drug meets the initial application conditions but does not guarantee inclusion in the basic medical insurance catalog or commercial health insurance innovative drug catalog [1]